



WPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas

Vancouver, British Columbia – April 27, 2021 – WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “**Company**” or “**WPD**”) a clinical-stage pharmaceutical company, is pleased to announce that it will attend the 10th Annual Congress of the Polish Society of Pediatric Oncology and Hematology to be held on May 6-8, 2021.

During the Congress, WPD will present the key assumptions of the WPD-201P Clinical Trial Protocol, which is planned to start in Q2 2021, as a part of the research project: “New approach to glioblastoma treatment addressing the critical unmet medical need“, granted by National Research and Development Center (“**NRDC**”) and co-financed by the European Union, under the Smart Growth Operational Program 2014-2020.

Berubicin is a second-generation anthracycline candidate for the treatment of a number of Central Nervous System Cancers, including Glioblastoma Multiforme (GBM) and Malignant Gliomas. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin was developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center, and demonstrated positive responses that include one durable complete response in a Phase 1 human clinical trial conducted previously by Reata Pharmaceuticals, Inc.

Mariusz Olejniczak, CEO of WPD commented, “*We are very excited for the ability to share our Phase I pediatric clinical trial protocol with the members of the pediatric oncology society. This will be a great opportunity to promote our project and to establish the possibility for future cooperation.*”

WPD also announces it has engaged Strikepoint Media LLC. (“**Strikepoint**”), to provide digital marketing and brand awareness support. The Company has agreed to pay Strikepoint US\$50,000 for a 3 month digital media term commencing on April 26, 2021. Strikepoint will not receive any securities of the Company as compensation for their services.

About WPD Pharmaceuticals

WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has licensed in certain countries 10 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things. The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes for most compounds 30 countries in Europe and Asia, including Russia.

On Behalf of the Board

'Mariusz Olejniczak'

Mariusz Olejniczak
CEO, WDP Pharmaceuticals

Contact:

Email: investors@wpdpharmaceuticals.com
Tel: 604-428-7050
Web: www.wpdpharmaceuticals.com

Investor Relations:

Arrowhead Business and Investment Decisions, LLC

Thomas Renaud
Managing Director
42 Broadway, 17th Floor
New York, NY 10004
Office: +1 212 619-6889
enquire@arrowheadbid.com

Cautionary Statements:

Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking statements. Forward-looking statements are statements that contemplate activities, events or developments that the Company anticipates will or may occur in the future. Forward-looking statements in this press release include that we can access the remainder of our NCRD grants and that WPD's drugs could be developed into novel treatments for cancer. These forward-looking statements reflect the Company's current expectations based on information currently available to management and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those projected. Factors which may prevent the forward looking statement from being realized is that competitors or others may successfully challenge a granted patent and the patent could be rendered void; that we are unable to raise sufficient funding for our research; that we may not meet the requirements to receive the grants awarded; that our drugs don't provide positive treatment, or if they do, the side effects are damaging; competitors may develop better or

cheaper drugs; and we may be unable to obtain regulatory approval for any drugs we develop. Readers should refer to the risk disclosure included from time-to-time in the documents the Company files on SEDAR, available at www.sedar.com. Although the Company believes that the assumptions inherent in these forward-looking statements are reasonable, they are not guarantees of future performance and, accordingly, they should not be relied upon and there can be no assurance that any of them will prove to be accurate. Finally, these forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update them except as required by applicable law.